Biotechnology - Genomic and Proteomics/IP Profile of Biggest for-profit companies in BGP/BGP Company Profiles - Data: Difference between revisions
Jump to navigation
Jump to search
(→Who) |
|||
| Line 46: | Line 46: | ||
===Commons-Based, Peer-Production, and Open Access News=== | ===Commons-Based, Peer-Production, and Open Access News=== | ||
* Amgen - marketing and R&D collaborations with (Powell pp. 72): ARRIS, Envirogen, Glycomex, Guilford, Interneuron, Regeneron, and Zynaxis. these companies develop the product that Amgen later produces and markets. Perhaps there are instances of commons-like sharing here. Further investigation needed | * Amgen - marketing and R&D collaborations with (Powell pp. 72): ARRIS, Envirogen, Glycomex, Guilford, Interneuron, Regeneron, and Zynaxis. these companies develop the product that Amgen later produces and markets. Perhaps there are instances of commons-like sharing here. Further investigation needed | ||
* Seems to be engaging in some instances of open-ended research with universities. e.g., collaboration with MIT's Whitehead institute (http://www.thefreelibrary.com/Axys+-+Amgen+Collaboration+Determines+the+X-Ray+Crystal+Structure+of...-a053047665) | |||
** Further instances of academic collaboration here: http://www.brighamandwomens.org/Pressreleases/PressRelease.aspx?PageID=201 | |||
** The results of some scientific collaborations are being released into the commons: http://en.scientificcommons.org/40666678 | |||
* Says its committed to sharing clinical testing results as soon as possible (http://switch.atdmt.com/action/deicrm_N53107Policy_6) | |||
==Genentech== | ==Genentech== | ||
Revision as of 18:39, 7 April 2009
NIH
Celera
Amgen
Who
- 16,900 employees (2008 Corporate report)
- History of acquisition (http://www.amgen.com/about/acquisitions.html):
- 1994 - Synergen, Inc.
- 2000 - Kinetix Pharmaceuticals, Inc.
- 2002 - Immunex Corporation
- 2004 - Tularik, Inc.
- 2006 - Abgenix, Inc.
- 2006 - Avidia, Inc.
- 2007 - Ilypsa, Inc.
- 2007 - Alantos Pharmaceuticals Holdings, Inc.
- Subsidiaries (http://www.fundinguniverse.com/company-histories/Amgen-Inc-Company-History.html):
- Amgen Australia Pty Ltd.;
- Amgen N.V.; Amgen Canada Inc.;
- Amgen Greater China Ltd.;
- Amgen GmbH (Germany);
- Amgen S.A. (France);
- Amgen S.p.A. (Italy);
- Amgen K.K. (Japan);
- Amgen B.V. (Netherlands);
- Amgen-Biofarmaceutica (Portugal);
- Amgen S.A. (Spain);
- Amgen (Europe) AG (Switzerland);
- Kirin-Amgen, Inc. (Switzerland);
- Amgen Limited (U.K.);
- Amgen Sales Corporation (West Indies).
- Unlike many biotech companies, has been consistently profitable. Net profit in 2006 was US$2.9Billion (http://www.pharmaceutical-business-review.com/companyprofile.asp?guid=8632C7AC-1633-4198-8551-BB79570C668D)
- Managed to turn itself from a drug research company into a pharmaceutical company while maintaining steady sales - extremely rare in the industry (http://www.fundinguniverse.com/company-histories/Amgen-Inc-Company-History.html)
- Founded in 1980. By 1986 was starting to turn a profit, but did so not through drug development but through research partnerships with established pharma firms
- 1987, develop erythropoietin (EPO), which stimulates red blood cell creation. Sold the marketing rights to Johnson&Johnson
- Epogen proves to hugely popular - over $250m in sales in 1991 alone
- Between 1992 and 1996, Amgen's R&D budget goes from $182 million to $663 million
What
- ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline
- drugs include: Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar / Mimpara and Nplate
Where
- Thousand Oaks, CA
News
Commons-Based, Peer-Production, and Open Access News
- Amgen - marketing and R&D collaborations with (Powell pp. 72): ARRIS, Envirogen, Glycomex, Guilford, Interneuron, Regeneron, and Zynaxis. these companies develop the product that Amgen later produces and markets. Perhaps there are instances of commons-like sharing here. Further investigation needed
- Seems to be engaging in some instances of open-ended research with universities. e.g., collaboration with MIT's Whitehead institute (http://www.thefreelibrary.com/Axys+-+Amgen+Collaboration+Determines+the+X-Ray+Crystal+Structure+of...-a053047665)
- Further instances of academic collaboration here: http://www.brighamandwomens.org/Pressreleases/PressRelease.aspx?PageID=201
- The results of some scientific collaborations are being released into the commons: http://en.scientificcommons.org/40666678
- Says its committed to sharing clinical testing results as soon as possible (http://switch.atdmt.com/action/deicrm_N53107Policy_6)
Genentech
Genzyme
Gilead Sciences
Biogen Idec
Cephalon
MedImmune
Celgene
Abraxis BioScience
ImClone Systems
IP Profile of Biggest for-profit companies in BGP